DNA Copy Number Signature to Predict Recurrence in Early-Stage Ovarian Cancer

Abstract

Through this project we have determined the status of copy number variation in recurrent and non-recurrent early stage high grade ovarian cancer using a large, fully annotated, consortium cohort of 384 samples from clinical trials (Aim 1). Integrated analysis of copy number variation and RNAseq results from same samples (generated from an ongoing DOD #OC110628) has been performed with clinical data to generate a predictor of the recurrence of early stage ovarian cancer (Aim 2).

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Nov 01, 2017
Accession Number
AD1095098

Entities

People

  • Michael J. Birrer

Organizations

  • Massachusetts General Hospital

Tags

DTIC Thesaurus Topics

  • Biomedical Research
  • Breast Cancer
  • Cancer
  • Chemotherapy
  • Clinical Trials
  • Consortiums
  • Cost Effectiveness
  • Data Analysis
  • Department Of Defense
  • Diseases And Disorders
  • Gene Expression
  • Health Services
  • Hospitals
  • Maryland
  • Neoplasms
  • Ovarian Cancer
  • Technology Transfer

Readers

  • Molecular and genetic basis of cancer.
  • Oncology (Cancer Research).